Effectiveness of Cloud-based Artificial Intelligence Aided Quality Control System in Korean National Lung Cancer Screening Program

Yeol Kim, MD, MPH, PhD

Professor, Graduate school of Cancer Science and Policy (GCSP)


Head, Center for Quality Control of National Lung Cancer Screening Program,

Family Physician, Center for Cancer Prevention & Detection, National Cancer Center Hospital,

National Cancer Center, Republic of Korea



Korean Lung Cancer Screening History






Korean Lung Cancer Screening project (K-LUCAS)

- Single arm, multicenter, prospective trial
- Targets 55-74 aged 30PY more smokers and quitters within 15Yrs
- Conducted from February 2017 to December 2018.
- K-LUCAS assessed the effectiveness, harm, and feasibility of population-based lung cancer screening in order to implement a national organized cancer screening program.
- K-LUCAS also evaluated the validation of the new standards of reporting form of LDCT using Lung-RADS and the quality of lung cancer screening by cloud-based network system.




Korean Lung Cancer Screening demonstration project (K-LUCAS) with cloud-based quality control system



CANCER CENTER

Computer Aid Diagnostic program based on network system using cloud





Comparison of Performance & Outcome Indicators, K-LUCAS vs NLST

Indicators	Calculation Formula	K-LUCAS	NLST	
Screening positive Rate	$rac{positive\ screening}{Total\ screening} imes 100$	15.3% 2091 / 13692	27.3% 7191 / 26309	
False Positive Rate	$\frac{False\ positive}{Non-cancer}\times 100$	14.7% (2091-88) / (13692-88)	26.6% (7191-270) / (26309-270)	
Non-cancer case per positive	$rac{\textit{Non} - \textit{cancer case}}{\textit{Positive screening}} imes extbf{100}$	95.8% (2091-88) / 2091	96.2% (7191-270) / 7191	
Cancer detection rate	$\frac{Total\ cancer\ diagnosed}{Total\ Screening} \times 100$	0.66% 90 / 13692	1.0% 270 / 26309	
Early stage detection rate	$\frac{\textit{Stage 1 or 2 cancers}}{\textit{Total cancer diagnosed}} \times 100$	70.0% 63 / 90	67.5% 458 / 679 (Total rounds)	
Cancer stage distribution	TNM stage 8 th edition	I: 48 (53.9%) II: 15 (16.9%) III: 17 (19.1%) IV: 9 (10.1%)	I: 407 (60.0%) II: 51 (7.5%) III: 126 (18.6%) IV: 95 (14.0%) (Total rounds)	



Cost-Effectiveness Analysis

LDCT screening vs no screening for high risk group

https://doi.org/10.4143/crt.2021.480

Cancer Res Treat, 2022;54(3):728-736

Original Article

Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project

Juyoung Kim 1012, Bogeum Cho?, Seon-Ha Kim?, Chang-Min Choi4, Yeol Kim?, Min-Woo Jo 1012

¹Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul.

²Department of Preventive Medicine, University of Ulsan College of Medicine, Seoul,

³Department of Pulmonology and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul,

⁵National Cancer Control Institute, National Cancer Center, Goyang, Korea

Purpose The aim of this study was to evaluate the cost utility of a pilot study of Korean Lung Cancer Screening Project.

Materials and Methods We constructed a Markov model consisting of 26 states based on the natural history of lung cancer according to the Surveillance, Epidemiology, and End Results summary stage (localized, regional, distant). In the base case, people aged 55-74 years were under consideration for annual screening. Costs and quality-adjusted life years were simulated to calculate the incremental cost utility ratio. Sensitivity analyses were performed on the uncertainty associated with screening target ages, stage distribution, cost, utility, mortality, screening duration, and discount rate.

Results The base case (US\$25,383 per quality-adjusted life year gained) was cost-effective compared to the scenario of no screening and acceptable considering a willingness-to-pay threshold of US\$27,000 per quality-adjusted life years gained. In terms of the target age of screening, the age between 60 and 74 years was the most cost-effective. Lung cancer screening was still cost-effective in the sensitivity analyses on the cost for treatment, utility, mortality, screening duration, and less than 5% discount rates, although the result was sensitive to a rise in positive rates or variation of stage distribution.

Conclusion Our results showed the cost-effectiveness of annual low-dose computed tomography screening for lung cancer in high-risk populations.

Key words Cost-benefit analysis, Lung neoplasms, Mass screening, Markov chains

Table 4. Results of cost utility analysis in the base case

	No screening	Screening ^{a)}	
Costs (USD)	26,961,422	45,132,450	
Incremental costs (USD)	-	18,171,028b)	
QALYs	117,223	117,939	
Incremental QALYs	-	716 ^{b)}	
ICUR	-	25,383b)	

ICUR, incremental cost-utility ratio; QALY, quality-adjusted life year; USD, United States dollars. ^{a)}Base case, ^{b)}The difference is due to rounding errors.




Fig. 2. Cost utility efficiency frontier. S, Scenario; S0, No screening; S1, age 55-79, S2, age 55-89; S3, age 55-99; S4, age 60-74; S5, age 65-74. Base case, S1, and S5 were excluded due to extended dominance.




Selection & Invitation for National Lung Cancer Screening Program in Korea

- Korea National Lung Caner Screening Program (KNLCS) launched from Aug. 2019 for the first time in the world.
- Korea national health insurance (NHI) has centralized database regarding people's smoking history on the basis of questionnaires submitted in national health screening program or public smoking cessation program
- NHI sent invitation letters to high-risk population aged 54–74 years current smokers with 30 Pack-Year smoking history



Process of National Lung Cancer Screening Program in Korea





Status of Korean National Lung Cancer Screening Program


PARTICIPATION RATE AND POSITIVE RATE

	Invited	Screened	Participation Rate	Positive Rate (Cat 3 + 4)	Category 4 (Suspicious)	Smoking Cessation Counselling Rate
2019	332,244	82,438	24.8%	9.1%	4.6%	44.8%
2020	359,212	92,903	25.9%	8.9%	4.1%	40.2%
2021	310,260	120,138	38.7%	8.7%	4.1%	35.0%

Distribution of positive rates among screening units participated in National lung cancer screening program


2021 Year

양성판정률(%)





Overview of Cloud-based Computer Aided Quality Control System (CQCS) using A.I. based Nodule Detection Program






A.I. based Computer-aided diagnosis Program for detection of pulmonary nodule




A.I. based Computer Program assist to diagnosis compare with past-examination






Auto calculation of coronary artery calcification (CAC)







Auto calculation of degree of emphysema by calculating low attenuated area (LAA)





Auto-generating reports based on national lung cancer screening program






Methods of analyzing the effectiveness of CQCS using in Korean national lung cancer screening program

- The study compared the quality index measured between groups of radiologists using and not using CQCS and before and after using CQCS.
- The quality index was evaluated by positive rates (the proportion of nodules classified as Lung-RADS category 3 and 4) and their variabilities across radiologists in screening units. Coefficient of quartile variation (CQV) of positive rates was used to calculate variabilities

$$(\theta^{\hat{}} CQV = (\theta^{\hat{}} 3 - \theta^{\hat{}} 1)/(\theta^{\hat{}} 1 + \theta^{\hat{}} 3)).$$


 Also, we measured reading time for evaluation a LDCT based on questionnaire to radiologists using CQCS.

Effectiveness of Cloud-based Computer Aided Quality Control System (CQCS) in Korean National Lung Cancer Screening






Effectiveness of Cloud-based Computer Aided Quality Control System (CQCS) in Korean National Lung Cancer Screening





Distribution of positive rates among screening hospitals participated in national lung cancer screening program

Positive rate (%)





Conclusion

- A cloud-based quality control system (CQCS) using artificial intelligence (AI) aided reading program
- showed effectiveness in assisting small lung nodule detection and measuring the nodule size,
- lowering variabilities of screening results across radiologists,
- and reducing burden of radiologists participated in mass lung cancer screening.



Thank you!

Yeol Kim MD, PhD drheat@ncc.re.kr